PDF(Pubmed)
Abstract：
Heart failure (HF) is a complex clinical syndrome with persistently high mortality. High-throughput proteomic technologies offer new opportunities to improve HF risk stratification, but their contribution remains to be clearly defined. We aimed to systematically review prognostic studies using high-throughput proteomics to identify protein signatures associated with HF mortality.
We searched four databases and two clinical trial registries for articles published from 2012 to 2023. HF proteomics studies measuring high numbers of proteins using aptamer or antibody-based affinity platforms on human plasma or serum with outcomes of all-cause or cardiovascular death were included. Two reviewers independently screened articles, extracted data, and assessed the risk of bias. A third reviewer resolved conflicts. We assessed the risk of bias using the Risk Of Bias In Non-randomized Studies-of Exposure tool.
Out of 5131 unique articles identified, nine articles were included in the review. The nine studies were observational; three used the aptamer platform, and six used the antibody platform. We found considerable heterogeneity across studies in measurement panels, HF definitions, ejection fraction categorization, follow-up duration, and outcome definitions, and a lack of risk estimates for most protein associations. Hence, we proceeded with a systematic review rather than a meta-analysis. In two comparable aptamer studies in patients with HF with reduced ejection fraction, 21 proteins were identified in common for the association with all-cause death. Among these, one protein, WAP four-disulfide core domain protein 2 was also reported in an antibody study on HFrEF and for the association with CV death. We proposed standardized reporting criteria to facilitate the interpretation of future studies.
In this systematic review of nine studies evaluating the association of proteomics with mortality in HF, we identified a limited number of proteins common across several studies. Heterogeneity across studies compromised drawing broad inferences, underscoring the importance of standardized approaches to reporting.
We searched four databases and two clinical trial registries for articles published from 2012 to 2023. HF proteomics studies measuring high numbers of proteins using aptamer or antibody-based affinity platforms on human plasma or serum with outcomes of all-cause or cardiovascular death were included. Two reviewers independently screened articles, extracted data, and assessed the risk of bias. A third reviewer resolved conflicts. We assessed the risk of bias using the Risk Of Bias In Non-randomized Studies-of Exposure tool.
Out of 5131 unique articles identified, nine articles were included in the review. The nine studies were observational; three used the aptamer platform, and six used the antibody platform. We found considerable heterogeneity across studies in measurement panels, HF definitions, ejection fraction categorization, follow-up duration, and outcome definitions, and a lack of risk estimates for most protein associations. Hence, we proceeded with a systematic review rather than a meta-analysis. In two comparable aptamer studies in patients with HF with reduced ejection fraction, 21 proteins were identified in common for the association with all-cause death. Among these, one protein, WAP four-disulfide core domain protein 2 was also reported in an antibody study on HFrEF and for the association with CV death. We proposed standardized reporting criteria to facilitate the interpretation of future studies.
In this systematic review of nine studies evaluating the association of proteomics with mortality in HF, we identified a limited number of proteins common across several studies. Heterogeneity across studies compromised drawing broad inferences, underscoring the importance of standardized approaches to reporting.
摘要：
背景：心力衰竭（HF）是一种复杂的临床综合征，死亡率居高不下。高通量蛋白质组学技术为改善HF风险分层提供了新的机会，但是他们的贡献还有待明确。我们旨在使用高通量蛋白质组学系统地回顾预后研究，以鉴定与HF死亡率相关的蛋白质特征。
方法：我们搜索了四个数据库和两个临床试验注册中心，查找2012年至2023年发表的文章。包括使用适体或基于抗体的亲和平台对人血浆或血清测量大量蛋白质的HF蛋白质组学研究,结果为全因死亡或心血管死亡。两名审稿人独立筛选文章，提取的数据，并评估了偏差的风险。第三位审阅者解决了冲突。我们使用非随机暴露研究中的偏倚风险工具评估偏倚风险。
结果：在确定的5131篇独特文章中，审查中包括了九篇文章。九项研究是观察性的；三项使用适体平台，六个人使用了抗体平台。我们在测量面板的研究中发现了相当大的异质性，HF定义,射血分数分类，随访持续时间,和结果定义，和缺乏对大多数蛋白质协会的风险估计。因此，我们进行了系统评价,而不是荟萃分析.在两项可比较的适配体研究中，HF患者的射血分数降低，鉴定出21种与全因死亡相关的蛋白质。其中,一种蛋白质,WAP四二硫键核心结构域蛋白2也在HFrEF和与CV死亡的关联的抗体研究中报道。我们提出了标准化报告标准，以促进对未来研究的解释。
结论：本系统综述了9项评估蛋白质组学与HF死亡率相关的研究，我们在几项研究中发现了有限数量的共同蛋白质.研究中的异质性损害了广泛的推论，强调标准化报告方法的重要性。
方法：我们搜索了四个数据库和两个临床试验注册中心，查找2012年至2023年发表的文章。包括使用适体或基于抗体的亲和平台对人血浆或血清测量大量蛋白质的HF蛋白质组学研究,结果为全因死亡或心血管死亡。两名审稿人独立筛选文章，提取的数据，并评估了偏差的风险。第三位审阅者解决了冲突。我们使用非随机暴露研究中的偏倚风险工具评估偏倚风险。
结果：在确定的5131篇独特文章中，审查中包括了九篇文章。九项研究是观察性的；三项使用适体平台，六个人使用了抗体平台。我们在测量面板的研究中发现了相当大的异质性，HF定义,射血分数分类，随访持续时间,和结果定义，和缺乏对大多数蛋白质协会的风险估计。因此，我们进行了系统评价,而不是荟萃分析.在两项可比较的适配体研究中，HF患者的射血分数降低，鉴定出21种与全因死亡相关的蛋白质。其中,一种蛋白质,WAP四二硫键核心结构域蛋白2也在HFrEF和与CV死亡的关联的抗体研究中报道。我们提出了标准化报告标准，以促进对未来研究的解释。
结论：本系统综述了9项评估蛋白质组学与HF死亡率相关的研究，我们在几项研究中发现了有限数量的共同蛋白质.研究中的异质性损害了广泛的推论，强调标准化报告方法的重要性。
